Adjuvant Therapy of Breast Cancer V

1. Front Matter

   Pages I-XIV

   PDF

2. Introduction

   1. The Control of Breast Cancer: A Look into the Future

      • U. Veronesi

      Pages 1-4

3. Epidemiology and Genetics of Breast Cancer

   1. Familial Breast Cancer

      • B. L. Weber

      Pages 5-16

   2. The Food-Derived Heterocyclic Amines and Breast Cancer: A 1995 Perspective

      • E. G. Synderwine

      Pages 17-25

   3. Menstrual Cycle Timing of Breast Cancer Resection

      • W. J. M. Hrushesky

      Pages 27-40

   4. Summary

      • M. H. N. Tattersall

      Pages 41-42

4. Biology of Breast Cancer

   1. Peptide Growth Factors and Breast Cancer Treatment: Recent Translational Research

      • M. Pollak

      Pages 43-49

   2. Single-Chain Fusion Toxins for the Treatment of Breast Cancer: Antitumor Activity of BR96 sFv-PE40 and Heregulin-PE40

      • C. B. Siegall

      Pages 51-60

   3. Tamoxifen and Endometrial Cancer: From Experiment to Patient

      • V. J. Assikis, V. C. Jordan

      Pages 61-71

   4. Summary

      • A. L. Harris

      Pages 73-75

5. Prognosis of Response and Tumor Markers

   1. Review of Known Prognostic Variables

      • M. Kaufmann

      Pages 77-87

   2. Prognostic Variables and Future Predictors of Behaviour and Response

      • B. A. Gusterson

      Pages 89-100

   3. Serum (Circulating) Tumor Markers for Breast Cancer

      • D. F. Hayes

      Pages 101-113

   4. Summary

      • M. Baum

      Pages 115-122

6. Screening for Breast Cancer and Treatment of Early Lesions (Ductal Carcinoma In Situ)

   1. A Critical Review of Screening for Breast Cancer

      • M. Rosselli Del Turco

      Pages 123-130

   2. Ductal Carcinoma In Situ

      • R. G. Margolese

      Pages 131-138

   3. Intraductal Breast Carcinoma: Experiences from The Breast Center in Van Nuys, California

      • M. J. Silverstein, D. N. Poller, A. Barth, J. R. Waisman, J. A. Jensen, R. Masetti et al.

      Pages 139-153

   4. Summary

      • John F. Forbes

      Pages 155-157

7. Surgery for Breast Cancer: Special Issues

   1. Surgical Treatment of Breast Cancer Relapse

      • R. G. Margolese

      Pages 159-167

   2. Primary and Secondary Breast Reconstruction with Special Emphasis on the Use of Prostheses

      • J. Y. Petit, M. Rietjens, C. Garusi, D. Capko

      Pages 169-175

We often hear physicians, health care professionals, poli­ ticians, and patient advocates that "nothing has happened in the treatment of breast cancer," since patients with breast cancer, the most frequent neoplastic condition in women in industrialized countries, are continuing to suffer relapse and succumb to this dreadful disease! This negativistic attitude does not seem to be justified, but, why is the transmission of clinical trial results into general practice, and with it progress, such a slow process? After many decades of frustrating stagnation of long-term survival expectations, in all stages of early, oper/lble breast cancer treated only by surgery and locoregional radio­ therapy, adjuvant systemic therapy (chemo- as well as endocrine treatments) clearly showed to significantly benefit in terms of disease-free and overall survival. This evolution has been extensively expounded on by the Worldwide Oxford Overview and the Expert Consensus Panel at the fourth International Conference 'on Adjuvant Therapy of Primary Breast Cancer in St. Gallen (Early Breast Cancer Trialists' Collaborative Group 1992; Glick et al. 1992). What has happened since then? During the past 3-5 years, several new concepts and treatment strategies have emerged and have been studied in various major breast cancer groups and treatment centers worldwide. Some of these can already be considered to assist in the primary treatment of operable breast cancer today, while others are . still undergoing clini,cal trials for better definition of their practical usefulness.

• adjuvant therapy
• breast cancer
• cancer
• cancer prevention
• carcinoma
• clinical trial
• epidemiology
• fertility
• genetics
• hormones
• prevention
• screening
• surgery
• systemic therapy
• tumor

• Department of Medicine C, Kantonsspital, St. Gallen, Switzerland

  Hans Jörg Senn, Beat Thürlimann

• Division of Biostatistics, Dana Farber Cancer Institute, Boston, USA

  Richard D. Gelber

• Ospedale Civico, Lugano, Switzerland

  Aron Goldhirsch

Policies and ethics